Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

SAN DIEGO, February 8, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US. [i]  

"People affected by EB suffer skin blisters and almost constant, acute pain and scarring," said the study's Principal Investigator, H. Alan Arbuckle , MD, Section Head Pediatric Dermatology Kaiser Permanente Colorado, Wound Care Consultant, Epidermolysis Bullosa Center of Excellence, The Children's Hospital, Aurora Colorado . "The current standard of care is daily wound care, bandaging and pain management. I am excited to be involved in testing the efficacy and safety of ABH001 as a potential treatment option for these patients."  

ABH001 for EB has been granted an orphan drug designation in the US and EU, and has also received Fast Track designation from the US Food and Drug Administration (FDA), which is aimed at facilitating the development and expediting the review of drugs and biologics that fill an unmet medical need. In addition, the European Medicines Agency's Pediatric Committee has agreed on a pediatric investigation plan for ABH001 for the treatment of EB.

The new Phase 3 study is a multi-site, prospective, randomized, open-label, intra-subject controlled trial evaluating the efficacy and safety of ABH001 to initiate healing and reduce the wound surface area of selected stalled, chronic cutaneous wounds associated with generalized EB. Approximately 20 subjects with generalized EB age
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... 2015  SeraCare Life Sciences, a leading partner ... that it has signed a Cooperative Research and ... (NCI), part of the National Institutes of Health, ... cancer assays.  The CRADA will investigate the development ... DNA biosynthetics spiked into a genomic DNA background ...
(Date:6/26/2015)... YORK and MUMBAI, India ... (BSE: 532540, NSE: TCS) a leading global IT services, ... been designated as a Leader in Worldwide Life Sciences ... in the " IDC MarketScape: Worldwide Life Science R&D ... report. The report evaluated eight leading ...
(Date:6/26/2015)... ... ... ReliantHeart, Inc. , an innovative supplier of advanced mechanical circulatory assist technologies ... (HA5) to the 68th consecutive implant, there has been no evidence of de novo ... referred to as de novo thrombus. De novo thrombus can hide under the impeller ...
(Date:6/25/2015)... , ... June 25, 2015 , ... ... State University will enjoy (8) new chemistry laboratories, each exclusively using filtered fume ... Erlab’s team finished installing the (49) filtered fume hoods needed for their Organic, ...
Breaking Biology Technology:SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 4HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3This Summer Erlab Completes the Largest Installation of Filtered Fume Hoods in the World 2
... Next Clinical StudiesOMAHA, Neb. and HOUSTON, May 11 ... Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM), ... and NuroPro(R) PD tests for Alzheimer,s and Parkinson,s ... meeting in Seattle, WA. The NuroPro tests help ...
... Inc. (Pink Sheets: NNLX) is pleased to announce the ... and target research and development efforts for products. ... vastly expanded scope of expertise in both medicine and ... of numerous NanoLogix patents, has resigned from the NanoLogix ...
... Panel DiscussionATLANTA, May 11 , WHAT: GeoVax Labs, ... publicly traded biopharmaceutical company developing human, ... Virus) and other ... the future and plans to expand preventative trials, currently in, ...
Cached Biology Technology:Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting 2Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting 3Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting 4Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting 5A Global View: NanoLogix Creates Science Advisory Board 2A Global View: NanoLogix Creates Science Advisory Board 3A Global View: NanoLogix Creates Science Advisory Board 4A Global View: NanoLogix Creates Science Advisory Board 5
(Date:6/25/2015)... PRINCETON, N.J. , June 25, 2015  TAKE ... awarded a patent by the United States Patent and ... Data Standardization". This process leverages TAKE Solutions, Clinical Accelerators ... by over 50% (when compared to standardization without the ... At the heart ...
(Date:6/24/2015)... June 22, 2015 ... addition of the "Huawei Ascend Mate 7 ... to their offering. Huawei,s technological choice ... opposite direction than Apple,s and Samsung,s one. The ... developed by Fingerprint Cards, a main actor in ...
(Date:6/23/2015)... 2015   Valencell, a leader in ... a recent study that illustrates its PerformTek biometric ... activity. In a study conducted at Valencell,s Biometric ... the Apple Watch against a chest strap – ... activity. The study demonstrated that Valencell,s biometric technology ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... [Brown University] If you want to understand a novel, it ... up the plot from somewhere in the middle. The same goes ... sense of it is to look at it head to tail. ... University, DNA molecules have a convenient tendency to cooperate. The ...
... colleagues have shown that one of the mechanisms involved in hearing ... that isn,t interesting enough, the UI scientists advanced their knowledge of ... by making use of the fruit fly "love song." To ... to know that the auditory system of the fruit fly contains ...
... Parents of newborn babies are always creeping into the nursery ... Alternatively, they might let baby sleep in their room, hoping ... too late. In future, a romper suit with an integrated ... stops breathing. The cornerstone of the sensor system is a ...
Cached Biology News:DNA prefers to dive head first into nanopores 2DNA prefers to dive head first into nanopores 3UI researcher learns mechanism of hearing is similar to car battery 2Romper suit to protect against sudden infant death 2Romper suit to protect against sudden infant death 3
HybriWell seals securely to a microscope slide surface in seconds to enclose single or multiple specimens in a small reagent volume and eliminate evaporation....
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... Human IgM Assay Kit to address the ... assay for Human IgM that eliminates the ... a simple mix-and-read assay that allows the ... ng/ml in approximately 30 minutes. The Pierce ...
AC input: 230 V...
Biology Products: